Umoja secures $100m to advance CAR-T cell therapy pipeline

Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy pipeline. Double Point Ventures and DCVC Bio jointly led the round, with...